TD Cowen raises Aurinia Pharmaceuticals price target on cost outlook
TD Cowen raised its price target for Aurinia Pharmaceuticals (AUPH) to $18 from $17, citing updated R&D cost estimates and durable growth of Lupkynis. The stock trades at $16.74, suggesting 7% upside. Aurinia also settled a patent dispute with Teva, extending voclosporin's exclusivity to 2036. Analysts expect continued revenue growth.
How this was made
The 30-second read
Why it matters
The revised target may trigger short‑term buying interest and modest price appreciation.
Market read
Analyst price‑target upgrades are a common catalyst for small‑cap biotech moves.
What to watch
Potential competitive pressure on voclosporin if generic entry is delayed beyond expectations.
Background
TD Cowen's analyst team updated its valuation model ahead of the biotech Q3 earnings preview.
Ticker impact
TD Cowen raised Aurinia Pharmaceuticals' price target to $18 from $17, citing lower R&D cost estimates and updated share count.
likely upward pressure as investors price in the higher target.
The new target reflects improved cost outlook and durable drug growth, which can attract buying.
Market effects
May boost sentiment for biotech sector as cost‑control improvements are highlighted.
Primarily U.S. biotech investors; limited broader regional effect.
Limited to investors tracking small‑cap biotech stocks.
Counterpoint
The price target increase could be premature if R&D cost reductions are not realized.
Key entities
- companyAurinia Pharmaceuticals
Biotech firm developing voclosporin and other therapies.
- analyst_firmTD Cowen
Equity research firm providing the price target upgrade.
